title: [Treatment of chronic allergic blepharoconjunctivitis].
abstract: OBJECTIVE
  to evaluate the effectiveness of therapeutic eyelid hygiene in the treatment of chronic, or perennial, allergic blepharoconjunctivitis (ABC).
  
  
  METHODS
  A total of 30 patients with chronic ABC (11 men, 19 women aged 25-41 years; disease duration 2-4 years) were examined before and after a treatment course which included instillations of olopatodine hydrochloride instillations (1 mg/ml, 2 times daily) and hyaluronic acid (2 mg/ml, 3-4 times daily). Patients from the main group (18 patients, 36 eyes) additionally practiced therapeutic eyelid hygiene using Blepharoshampoo, Blepharolotion or Blepharosalfetka, and Blepharogel-1 (2 times daily). The control group was given only anti-allergic therapy and tear substitutes. Conventional ophthalmological examination, allergy testing, ABC signs and symptoms evaluation, Schirmer's 1 and Norn's tests, tear film break-up time evaluation, assessment of meibomian gland function, optical coherence tomography (OCT) for tear meniscus, xerosis index evaluation and lissamine green staining for lid wiper epitheliopathy, and anterior segment photography with further computer morphometry were performed in all patients.
  
  
  RESULTS
  Dry eye signs and symptoms, including combined lipid, water, and mucus tear deficiency, were found in all patients with chronic ABC. Patients from the main group demonstrated a significantly greater decrease of integral indices of subjective ocular discomfort, reduction of chronic ABC signs as well as more pronounced improvement of the meibomian gland function, appearance of the lid wiper region, tear film break-up time, results of the OCT-meniscometry, and xerosis index.
  
  
  CONCLUSIONS
  Introduction of therapeutic eyelid hygiene to the complex treatment of chronic allergic blepharoconjunctivitis with the aim of resolving secondary dry eye symptoms enhances the effectiveness of the treatment.
authors.forename: S V
authors.initials: SV
authors.lastname: Ianchenko
authors.forename: S N
authors.initials: SN
authors.lastname: Sakhnov
authors.forename: A V
authors.initials: AV
authors.lastname: Malyshev
authors.forename: N V
authors.initials: NV
authors.lastname: Fedotova
authors.forename: O Iu
authors.initials: OIu
authors.lastname: Orekhova
authors.forename: I V
authors.initials: IV
authors.lastname: Grishchenko
mesh_terms: D000328:Adult; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D001762:Blepharitis / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D002908:Chronic Disease; D003131:Combined Modality Therapy; D003233:Conjunctivitis, Allergic / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D015352:Dry Eye Syndromes / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage*; D006920:Hygiene; D065346:Lubricant Eye Drops / Q000627:therapeutic use*; D008297:Male; D008537:Meibomian Glands / Q000503:physiopathology; D013501:Surface-Active Agents / Q000008:administration & dosage; D016896:Treatment Outcome; D055675:Viscosupplements / Q000008:administration & dosage
chemical_list: D018926:Anti-Allergic Agents; D065346:Lubricant Eye Drops; D013501:Surface-Active Agents; D055675:Viscosupplements; D006820:Hyaluronic Acid